SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-13-083246
Filing Date
2013-11-12
Accepted
2013-11-12 08:00:45
Documents
10
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q a13-19466_110q.htm 10-Q 828235
2 EX-31.1 a13-19466_1ex31d1.htm EX-31.1 10685
3 EX-31.2 a13-19466_1ex31d2.htm EX-31.2 11303
4 EX-32.1 a13-19466_1ex32d1.htm EX-32.1 7395
  Complete submission text file 0001104659-13-083246.txt   5303503

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT mrtx-20130930.xml EX-101.INS 729448
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20130930.xsd EX-101.SCH 47157
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20130930_cal.xml EX-101.CAL 47088
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20130930_def.xml EX-101.DEF 150203
9 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT mrtx-20130930_lab.xml EX-101.LAB 595085
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20130930_pre.xml EX-101.PRE 277212
Mailing Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 (514) 337-3333
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 131207025
SIC: 2834 Pharmaceutical Preparations